Cue Biopharma (CUE) Expected to Announce Quarterly Earnings on Thursday

Cue Biopharma (NASDAQ:CUE) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Cue Biopharma to post earnings of ($0.10) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. The business had revenue of $2.95 million for the quarter, compared to analysts’ expectations of $2.00 million. Cue Biopharma had a negative net margin of 469.35% and a negative return on equity of 230.13%. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Stock Up 0.3%

Shares of NASDAQ:CUE opened at $0.68 on Wednesday. Cue Biopharma has a 1-year low of $0.54 and a 1-year high of $1.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.60 and a quick ratio of 1.60. The stock has a market cap of $52.49 million, a P/E ratio of -1.22 and a beta of 1.49. The firm has a fifty day moving average price of $0.75 and a 200 day moving average price of $0.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cue Biopharma stock. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 730.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 83,000 shares of the company’s stock after acquiring an additional 73,000 shares during the quarter. Northwestern Mutual Wealth Management Co. owned 0.11% of Cue Biopharma worth $57,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cue Biopharma in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.